Tuesday, July 8, 2025 7/8/2025

Biotin Orthogonal Streptavidin System (BOSS) for Drug Pre-Targeting

Award Number: F32GM149148
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 02/01/2023
PERIOD OF PERFORMANCE END DATE: 06/04/2024

Group Awards By:

View Award Description

Biotin Orthogonal Streptavidin System (BOSS) for Drug Pre-Targeting - Abstract Streptavidin (SA) and biotin have the strongest known binding interaction in nature, with a KD in the femtomolar range (4.8x10-14 M). This extraordinary binding affinity has led to its ubiquitous use in biomedical research and diagnostics. Though SA/biotin enjoys success in many applications, abundant endogenous biotin attenuates assay sensitivity. Moreover, SA is a highly immunogenic foreign protein, which limits its use in therapeutic applications such as pretargeted immunotherapy (PTI). Mirror-image SA and biotin (D-SA/L-biotin) offer an elegant solution to these problems. For example, D- Proteins are inert to L-proteases and therefore cannot be digested for MHC presentation to the immune system. This property means that D-SA will have greatly decreased immunogenicity and increased half-life compared to L-SA. Additionally, symmetry dictates that the mirror-image pair (D-SA/L-biotin) will have the exact same exceptional affinity as the natural pair (L-SA/D-biotin). Importantly, we have discovered that D-biotin has minimal binding to D-SA. Therefore, we propose that D-SA/L-biotin can be used as a biotin orthogonal streptavidin system (BOSS). We hypothesize that the orthogonality of BOSS, along with D-SA’s low immunogenicity, will overcome the limitations of natural SA/biotin. We will chemically synthesize D-SA using solid-phase peptide synthesis with D-amino acids and native chemical ligation. We will then replicate a previously reported SA PTI method using BOSS. We will attach this D-SA to the C-terminus of the antibody fragment (scFv) used in the previous study (scFv-D-SA) and will recombinantly express its L-counterpart (scFv-L-SA). This scFv binds to GD2, a cell-surface glycosphingolipid that is upregulated in neuroblastoma (NB). We will first measure the efficacy of scFv-D-SA in NB cells using fluorescence microscopy. We will attach a red fluorophore to D-biotin and magenta fluorophore to L-biotin to determine the relative binding of scFv-D-SA and scFv-L-SA to the NB cells and a panel of control cells. We will then test our BOSS PTI method in mice xenografted with NB cells using fluorescence-based full-body imaging to look for enhanced fluorescence localized around the tumor. We expect that BOSS will dramatically improve current pretargeting efforts. Moreover, given the ubiquity of biotin/SA-based systems throughout biomedical science, we also expect BOSS to be widely applicable and relevant to proximity labeling, diagnostic testing, and any method that suffers from SA immunogenicity and biotin interference.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$46,768 )
2025	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Biomedical Research and Research Training	000	2	6/11/2025	NON-COMPETING CONTINUATION	-$46,768
														Subtotal = -$46,768

Issue Date FY: 2024 ( Subtotal = $77,284 )
2024	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Biomedical Research and Research Training	001	2	5/14/2024	NON-COMPETING CONTINUATION	$5,284
2024	2024	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Biomedical Research and Research Training	000	2	1/5/2024	NON-COMPETING CONTINUATION	$72,000
														Subtotal = $77,284

Issue Date FY: 2023 ( Subtotal = $71,580 )
2023	2023	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Biomedical Research and Research Training	002	1	2/9/2023	NEW	$0
2023	2023	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Biomedical Research and Research Training	000	1	1/27/2023	NEW	$69,674
2023	2023	UNIVERSITY OF UTAH, THE	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Biomedical Research and Research Training	001	1	2/9/2023	NEW	$1,906
														Subtotal = $71,580

Grand Total All Awards = $102,096

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biotin Orthogonal Streptavidin System (BOSS) for Drug Pre-Targeting

Award Number: F32GM149148

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 02/01/2023

PERIOD OF PERFORMANCE END DATE: 06/04/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer